analytical standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Headaches Enlargement of the hands, feet, nose, lips, and ears, and a general thickening of the skin Soft tissue swelling of internal organs, notably the heart with the attendant weakening of its muscularity, and the kidneys, also the vocal cords resulting in a characteristic thick, deep voice and slowing of speech Generalized expansion of the skull at the fontanelle Pronounced brow protrusion, often with ocular distension (frontal bossing) Pronounced lower jaw protrusion (prognathism) with attendant macroglossia (enlargement of the tongue) and teeth spacing Hypertrichosis, hyperpigmentation and hyperhidrosis Skin tags Carpal tunnel syndrome
ISBN 0-451-23706-4 OCLC 741538553 Megellas, James. All the Way to Berlin: A Paratrooper at War in Europe. New York: Ballantine Books, 2003. ISBN 0-89141-784-2 OCLC 50810144 Mrozek, Steven J. 82nd Airborne Division. Paducah, Ky: Turner Pub. Co, 1997. ISBN 1-56311-364-3 OCLC 52963023 Nordyke, Phil. All American, All the Way: The Combat History of the 82nd Airborne Division in World War II. St. Paul, MN: Zenith Press, 2005. ISBN 0-7603-2201-5 OCLC 60757547 Nordyke, Phil. The All Americans in World War II: A Photographic History of the 82nd Airborne Division at War. St. Paul, MN: Zenith Press, 2006. ISBN 0-7603-2617-7 OCLC 64961665 Pushies, Fred (2008). 82nd Airborne. Military Power. Minneapolis, Minnesota: Zenith Press. p. 128. ISBN 978-0-7603-3465-2. OCLC 199464749. Ruggero, Ed. Combat Jump: The Young Men Who Led the Assault into Fortress Europe, July 1943. New York: HarperCollins, 2003. ISBN 0-06-008875-3 OCLC 51978036 Saunders, Tim. Nijmegen, Grave, and Groesbeek. Barnsley, South Yorkshire: Leo Cooper, 2001. ISBN 0-85052-815-1 OCLC 49594764 Thompson, Leroy. The All Americans: The 82nd Airborne. Newton Abbot, Devon: David & Charles Publishers, 1988. ISBN 0-7153-9182-8 OCLC 19393819 Zinsmeister, Karl. Boots on the Ground: A Month with the 82nd Airborne in the Battle for Iraq. New York: Truman Talley Books/St. Martin's Press, 2003. ISBN 0-312-32663-7 OCLC 52775207 Zinsmeister, Karl, Dan Jurgens, and Raul Trevino. Combat Zone: True Tales of GIs in Iraq. New York, NY: Marvel Comics, 2005. ISBN 0-7851-1516-1 OCLC 61373604
The classification presented here, for recent cephalopods, follows largely from Current Classification of Recent Cephalopoda (May 2001), for fossil cephalopods takes from Arkell et al. 1957, Teichert and Moore 1964, Teichert 1988, and others. The three subclasses are traditional, corresponding to the three orders of cephalopods recognized by Bather. Class Cephalopoda († indicates extinct groups)
== Development == The world's first major one-place study is believed to have been an attempt started in Austria in 1920 by Konrad Brandner to chart a complete genealogy of the population of the Steiermark region. After the Nazi takeover of Germany, the Nazi farming authority Reichsnährstand began a nationwide campaign in 1937 to document the "Aryan blood" of countryfolk by documenting the ancestry of every village in a Dorfsippenbuch. 30 such books were published by 1940. Nazi schoolteachers led the copying of parish registers onto index cards, and boasted that 30,000 Heimat histories would be written, but the Second World War brought this project to a halt. Though genealogy in Germany was to take decades to shake off this evil association, some enthusiasts resumed work on the card indexes or typewritten lists left from before the war, and the first new one-place study, now renamed an Ortssippenbuch, appeared in 1956. Later the term was changed yet again, to de:Ortsfamilienbuch. More than 3,000 have appeared, with a trend away from print to electronic publication.
Sources: en.wikipedia.org
In what some have called the First Cold War, from Britain's intervention in the Russian Civil War in 1918 to its uneasy alliance with the Soviet Union against the Axis powers in 1941, British distrust of the revolutionary and regicidal Bolsheviks resulted in domestic, foreign, and colonial policies aimed at resisting the spread of communism. This conflict after 1945 took on new battlefields, new weapons, new players, and a greater intensity, but it was still fundamentally a conflict against Soviet imperialism (real and imagined). The idea of long-term continuity is a minority scholarly view that has been challenged. Frank Ninkovich writes:
γ-Melanocyte-stimulating hormone (γ-MSH) is an endogenous peptide hormone and neuropeptide. It is a melanocortin, specifically, one of the three types of melanocyte-stimulating hormone (MSH), and is produced from proopiomelanocortin (POMC). It is an agonist of the MC1, MC3, MC4, and MC5 receptors. It exists in three forms, γ1-MSH, γ2-MSH, and γ3-MSH. γ-MSH regulated cardiovascular functions. γ-MSH effects are measured through the effects it has on the central neural pathway dispersed throughout the kidney. It is not moderated based on tubular sodium transport. Gamma-MSH activates MC3R in renal tubular cells by limiting sodium absorption by inhibiting the central neural pathway. This regulates sodium balance and blood pressure. If MC3R is absent then there is resistance in γ-MSH which results in hypertension on HSD.
== See also == Crystal structure prediction Dynamical system Memetics Metastability Ostwald's rule of stages Protein folding#Misfolded proteins Prion Protein folding#Energy landscape of protein folding Proteinopathy#Seeded induction Schild's Ladder Self-replicating machine Self-replication Strangelet#Potential propagation
Gramicidin S differs from other gramicidin types in that it is a cationic cyclic decapeptide and has a structure of an anti-parallel beta-sheet. Gramicidin S molecule is amphiphilic, with hydrophobic amino acids (D-Phe, Val, Leu side chains) and charged aminoacid (L-Orn). It exhibits strong antibiotic activity towards Gram-negative and Gram-positive and even several pathogenic fungi. The mode of action is not entirely agreed upon, but it is generally accepted that it is disruption of the lipid membrane and enhancement of the permeability of the bacterial cytoplasmic membrane. Unfortunately, being hemolytic at even low concentrations, gramicidin S is only used as topical applications at present. Additionally, Gramicidin S has been employed as a spermicide and therapeutic for genital ulcers caused by sexually transmitted disease.
Gaits can be grouped into categories according to their patterns of support sequence. For quadrupeds, there are three main categories: walking gaits, running gaits and leaping gaits. Walking is the most common gait, where some feet are on the ground at any given time, and found in almost all legged animals. Running is considered to occur when at some points in the stride all feet are off the ground in a moment of suspension.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.